Burfiralimab

DB18935InvestigationalProtein Based Therapies

Burfiralimab is under investigation in clinical trial NCT06306339 (A Study to Assess the Efficacy and Safety of Burfiralimab (Hzvsf-v13) and DMRD (Disease-modifying Antirheumatic Drug)).

Mechanism: Pharmacologically active on Vimentin
Curator reviewed
Also known as: burfiralimab [INN] · IMMUNOGLOBULIN G4, ANTI-(HUMAN VIMENTIN) (HUMAN-MUS MUSCULUS .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS .KAPPA.-CHAIN, DIMER
Code names: hzVSF-v13

Resolves to

Compound

UNII82WF2WG4MPCAS2460809-80-5

Targets

P08670VIM

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Burfiralimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account